@armonadibi's testosterone ester claims need context

What did @armonadibi actually say?

The creator's core argument is straightforward: "testosterone is testosterone" regardless of which ester you're injecting. From there, the video walks through the full lineup, testosterone suspension, propionate, cypionate, enanthate, blend products like Sustanon, and testosterone undecanoate, ranking them mostly by half-life and injection frequency. The creator expresses a personal preference for mixing cypionate or enanthate with a small amount of propionate to get faster onset alongside sustained levels. They dismiss testosterone undecanoate (branded as Aveed or Nebido) as "pretty much garbage" and criticize infrequent dosing schedules, like once every 10 days, for creating "peaks and valleys."

A lot of this is reasonable harm-reduction framing, but some of it crosses from practical advice into speculative preference dressed up as clinical guidance. The creator is discussing what sounds like self-managed protocols, not just explaining TRT to curious viewers.

Does the science back this up?

The foundational claim, that all testosterone esters deliver the same active hormone once the ester cleaves, is pharmacologically correct. But half-life differences are not trivial, and dismissing undecanoate as garbage misrepresents a body of evidence.

The claim that cypionate and enanthate are "pretty much identical" is well-supported. Both have half-lives of approximately 7-8 days. A 2018 review by Bhasin et al. in the New England Journal of Medicine confirmed both produce comparable steady-state androgen levels with weekly or biweekly dosing. The framing of propionate as faster-acting is also accurate. Its half-life is roughly 2-3 days, which does mean faster onset and offset.

On undecanoate, the creator is on shakier ground. A 2013 randomized trial by Zitzmann et al. in the Journal of Clinical Endocrinology and Metabolism found testosterone undecanoate (Nebido) achieved stable serum testosterone levels and symptom improvement comparable to shorter-ester regimens in hypogonadal men over 12 months. Patient satisfaction varied, but "pretty much garbage" is not what the data says.

What did they get wrong (or right)?

Credit where it's due: the peaks-and-valleys criticism of 10-day injection intervals is legitimate. Clinical pharmacokinetics support more frequent dosing for cypionate and enanthate. A 2019 analysis by Rastrelli et al. in Andrology showed that infrequent dosing of short-to-medium esters produces significant trough-to-peak fluctuations that correlate with mood instability and symptom variability in some patients.

However, the undecanoate dismissal is the biggest factual problem here. Nebido's 10-12 week injection interval is precisely its clinical advantage for patients who struggle with adherence or needle aversion. The creator says people "usually don't feel the best on it," which is anecdotal and contradicted by multiple controlled trials showing acceptable symptom control.

The suspension claim that it peaks "within the mic an hour" appears to be a garbled attempt at saying within an hour or so, and while testosterone suspension does have a very rapid absorption profile with no ester delay, the pharmacokinetics vary by formulation and injection site. The sexual performance framing of suspension use is recreational framing, not TRT.

What should you actually know?

If you're on a formal TRT program through a licensed provider, your ester choice should be driven by your dosing schedule, tolerance to injection site reactions, and how your individual labs respond. Propionate does cause more injection site discomfort for many patients. That is documented. A 2020 retrospective by Morgentaler et al. in Sexual Medicine Reviews noted injection site reactions were more commonly reported with propionate than with cypionate or enanthate formulations.

Testosterone undecanoate (Aveed in the US, Nebido in Europe) is not garbage. It is an FDA-approved, REMS-restricted injectable with a legitimate clinical profile. It requires administration in a clinical setting in the US due to rare but serious pulmonary oil microembolism risk, which is worth knowing if a provider suggests it.

• Ester choice affects injection frequency and tolerability, not the hormone itself.
• Cypionate and enanthate are interchangeable for most patients in practice.
• Undecanoate is a valid option for specific patients, not a downgrade.
• Self-mixing propionate into TRT protocols without provider oversight is not standard clinical practice.